Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim

Inclusion Criteria:

- Age 18 years or over

- ECOG performance status 0-2

- Female with newly diagnosed, not previously treated with chemotherapy, stage I-III
breast cancer

- Planning to receive at least 4 cycles of adjuvant or neoadjuvant chemotherapy

- Medically eligible to safely receive adjuvant or neoadjuvant chemotherapy and
pegfilgrastim as determined by the investigator

- Planning to receive prophylaxis with pegfilgrastim starting in the first cycle and
continuing throughout each chemotherapy cycle of the study period

- Has provided informed consent

- Able to understand the content of the DVD material, in investigator's opinion

- Able to read and understand English

Exclusion Criteria:

- Planning to receive weekly chemotherapy

- Chronic use of NSAIDs or anti-histamines

- Ongoing chronic pain, or other painful conditions requiring treatment (including
immediate post-operative treatment of surgical or procedural-associated pain) as
determined by the investigator

- Chronic steroid use. Premedication related to the administration of taxanes, and use
of anti-emetics is allowed, per usual clinical practice

- Prior chemotherapy treatment

- Prior use of G-CSF

- Currently enrolled in another investigational device or drug study, or less than 30
days since ending another investigational device or drug study(s), or receiving other
investigational agent